ABSTRACT: FRFP binds to mineral at osteoblastic, osteoclastic, and quiescent surfaces, with accumulation likely modulated by vascular delivery. In vivo visualization and quantification of binding can be accomplished noninvasively in animal models through optical tomographic imaging.
INTRODUCTION
A CCURATE, NONINVASIVE TECHNIQUES for monitoring changes in skeletal metabolism are required for sensitive screening of disease-related events. Tools to monitor local changes in bone formation and resorption are critical for early screening of osteoporosis, arthritis, or tumor metastasis to bone, among others. Current techniques are either insensitive to spatial changes or rely on altered structure to infer cellular activity.
Standard radiological imaging assays such as DXA, Xray, CT, and MRI provide a snapshot of the sum effect of osteoblast and osteoclast activity on skeletal structure, but do not directly describe cellular events at the time of imaging. Serum and urine biochemical markers of bone turnover provide an accurate assessment of changes in bone formation and bone resorption in the body, but cannot localize aberrant activity to a specific skeletal site. Whereas the use of radiolabeled bisphosphonates for bone scintigraphy provides a means to monitor site-specific changes in metabolic activity, the use of radioactive agents has limited spatial resolution and does not allow for serial imaging over prolonged periods of time.
Molecular imaging techniques are emerging that report cellular activity by coupling specific cellular pathways or activities with optical reporter agents. Optical imaging in the near-infrared region of the spectrum offers an advantage over blue and green shifted molecular markers by allowing for high tissue penetration with low tissue autofluorescence, resulting in high signal-to-noise ratios during imaging.
(1) These techniques have proven useful and promising in early diagnosis of diseases such as cancer (2) and atherosclerosis. (3) Recently, investigators have begun applying molecular imaging techniques to questions of skeletal biology. (4) A putative bone binding agent has been designed to detect new bone formation in vivo by coupling a near-infrared fluorochrome to the bisphosphonate pamidronate. (5) Although this agent has been shown to highlight regions of the developing skeleton, specifically how and where this agent binds in the tissue remains to be described. Bisphosphonates have been shown to bind to mineral with some heterogeneity based on their dosing and molecular structure, (6, 7) and understanding where fluorochrome-labeled bisphosphonates bind in the bone matrix is critical to their use as an imaging tool. This study was designed to evaluate the binding of a far-red fluorescent pamidronate (FRFP) to bone on a local scale and to determine the effectiveness of this imaging strategy for in vivo monitoring of bone formation and resorption events.
MATERIALS AND METHODS

Probes
A commercially available FRFP (Osteosense; VisEn Medical, Woburn, MA, USA) was used in two distinct labeling wavelengths-Osteosense 680 (FRFP680, excitation 680 ± 10 nm; emission 700 ± 10 nm) and Osteosense 750 (FRFP750, excitation 750 ± 10 nm; emission 780 ± 10 nm). A protease-activated marker, Prosense 680 (PS680; VisEn Medical) was also used, (8) along with a noncleavable control probe composed of a d-enantiomer backbone and linker region (DC680). Adult mouse in vivo dose was 2 nmol in 150 l saline (13.3 M), or ∼80 nmol/kg body weight.
In vitro FRFP binding assay
To determine in vitro binding capacity of FRFP, dilutions of FRFP750 between 0 and 0.67 M were prepared and incubated with dentine slices in 96-well plates for 1 h at room temperature under constant mixing. The maximum concentration was chosen as 5% of the adult in vivo imaging dose based on previous results describing bisphosphonate bioavailability.
(7) After 1 h, dentine slices were removed from solution and rinsed in PBS for 1 h, at which point they were air dried and imaged under fluorescence reflectance imaging (bonSAI, Siemens Medical Solutions; excitation 748 nm/ emission 770 nm LP).
The effect of mineral content on FRFP binding was assessed by adding 0.67 M FRFP750 for 1 h to an intact dentine slice and a slice that had been demineralized in 0.5M EDTA for 16 h. Slices were rinsed in PBS, air dried, and imaged by fluorescence reflectance imaging to assess average FRFP binding to dentine surface. After fluorescence imaging, demineralization was verified by DXA with a GE Lunar Piximus 2 scanner.
Neonatal mouse imaging
To assess FRFP binding in vivo in newly mineralizing, immature bone, an 8-day neonatal mouse was imaged by fluorescence reflectance imaging 24 h after injection of 0.2 nmol of FRFP750 (15 l, IP). The mouse was killed immediately after imaging, and the tail was dissected free from the body and snap frozen in OCT for nondecalcified frozen sectioning. Sections of the tail vertebrae were imaged on a fluorescence microscope and compared with adjacent sections stained for alkaline phosphatase activity, presence of mineral by von Kossa staining, and collagen maturity using Masson's trichrome stain.
Adult mouse fluorescence molecular tomography
Fluorescence molecular tomography (FMT) is a quantitative technique capable of discriminating fluorescent signal deep within tissue through 3D tomographic reconstruction of a near-infrared fluorochrome data set. (9) To monitor FRFP binding in vivo both in deep and superficial skeletal sites, two 9-wk-old female nude mice were given 2 nmol of FRFP750 (150 l, IV) and imaged 24 h later by FMT (VisEn Medical; excitation laser/emission filter 745/775 nm). Reconstructed 3D FMT data sets were generated at 1.0 × 1.0 × 0.5-mm voxel size and used to compare fluorescent signal to bone location using subsequent CT scanning (Gamma Medica).
Bone defect healing
To assess FRFP binding in a tissue regeneration model, 7-to 8-wk-old male Balb/c mice were subjected to drilling injury. Under anesthesia, an incision was made to expose the antero-medial surface of the tibia. Using a 0.7-mm dental burr, a small hole was drilled into the tibial cortex under saline irrigation. The wound was flushed with saline, and the incision sutured closed. The defect size is not critical, and animals are typically able to bear weight normally within 1 h after surgery. A 2-nmol intravenous dose of FRFP was injected early (day 3, FRFP750, n ‫ס‬ 3), and late (day 7, FRFP750, n ‫ס‬ 3) after surgery. Mice were killed 24 h after probe administration, and limbs were dissected and snap frozen for nondecalcified histology. To assess longerterm probe binding, a separate group of mice (n ‫ס‬ 3) were injected on day 8 after surgery (FRFP680) and killed 6 days later for histology. A final group of animals (n ‫ס‬ 3) were double-labeled with FRFP750 on day 7 and FRFP680 on day 8 to assess binding of two separate wavelengths of probe and killed on day 14.
Orthotopic metastasis model
When injected orthotopically into bone, PC3 prostate cancer cells elicit an osteolytic response (10) and provide a means to monitor a primarily resorptive environment in bone. To assess FRFP binding in this regard, ∼100,000 PC-3 prostate cancer cells were suspended in 10-20 l of matrigel and directly injected into the proximal tibia of male nu/nu mice (n ‫ס‬ 5) at 9 wk of age following previously described protocols. (10) Contralateral tibias received comparable injections of saline alone. Mice were screened by X-ray at day 24 after injection, and received a 2-nmol dose of FRFP680 (150 l, IV) on day 28. FMT imaging was performed on day 29, after which mice were killed, and tibias were prepared for frozen, nondecalcified sectioning and fluorescence histology.
Tissue preparation effects
To test the effects of fixation and decalcification on probe stability in situ, FRFP signal was compared with two other
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imaging agents: PS680, a protease-activated marker whose fluorescence increases after cleavage of cathepsin Bsensitive linker, (8) and a noncleavable, nonbone binding control (DC680).
One male nu/nu mouse received a dual injection of PS680 and FRFP750, whereas a second mouse received a single injection of DC680 (2 nmol in 150 l/probe, IV). Mice were killed 7.5 h after probe administration, and left and right femora were carefully dissected free and cleaned of all soft tissue. Baseline fluorescence reflectance imaging was performed in both optical channels (680/700 nm: 1.5 s; 750/780 nm: 1.0 s), and femora were subsequently fixed in 4% paraformaldehyde for 58.5 h. Postfixation images were taken, and femora were decalcified in 0.5 M EDTA, with fluorescence imaging performed midway (24 h) and after (48 h) decalcification. Total femoral fluorescence was assessed for each femur at each imaging point, and left and right femoral values were averaged to obtain a representative measure of femur fluorescence. Postfixation, mid-, and postdecalcification fluorescence values were normalized by baseline values to determine percent change in femoral fluorescence with treatment.
Nondecalcified histology and staining
Based on results from decalcification, neonatal, defect, and metastasis specimens were snap frozen in OCT or 7% gelatin and sectioned nondecalcified using the Cryojane cutting system (Instrumedics, St Louis, MO, USA). Unfixed, fresh sections were imaged for FRFP fluorescence on a fluorescent microscope. On adjacent slides, alkaline phosphatase staining was performed using an alkaline phosphatase substrate kit (SK-5100; Vector Laboratories, Burlingame, CA, USA) following manufacturer's instructions. Masson's trichrome staining was performed using an Accustain Trichrome kit (HT15; Sigma Aldrich). von Kossa staining for presence of mineral was performed using a modified protocol. (11) 
RESULTS
In vitro binding assay
Dentine slices incubated for 1 h in FRFP750 revealed dose-dependent increases in fluorescence between 0 and 0.67 M (Fig. 1A) . Decalcification of dentine for 16 h resulted in a decrease of mineral content by 38% (11.3 versus 7 mg) and a subsequent 54% decrease in average FRFP binding (Fig. 1B) , confirming mineral as the primary binding target of FRFP.
Neonatal mouse imaging
Fluorescence reflectance imaging of a young, developing neonatal mouse showed high FRFP signal in superficial regions typical of active mineralization, including the mandible, wrist, paws, sternum, tibial growth plates, feet, spine, and tail ( Fig. 2A, left and middle) . No significant fluorescence arose from a noninjected control mouse ( Fig. 2A,  right) .
Fluorescence histology revealed FRFP deposition at the peripheral, mineralizing surfaces of the vertebral body and along mineralized surfaces central to the vertebra (Fig. 2B,  arrowheads) , ceasing before the zone of hypertrophic chondrocytes (Figs. 2B and 2C, dashed line). The signal seemed consistent spatially with the heaviest alkaline phosphatase (Fig. 2C, arrowheads) and Masson's trichrome (Fig. 2E , arrowheads) staining; however, some interior regions stained heavily by alkaline phosphatase did not reflect FRFP signal. von Kossa staining revealed a significant quantity of mineralized matrix in the interior of the vertebral body, which was not labeled by FRFP (Fig. 2D) . No FRFP signal was observed in the nonmineralized intervertebral disc (Figs. 2F-2I), consistent with the expectation that FRFP binds to mineral preferentially over soft tissue.
Adult mouse FMT
FMT imaging in adult mice revealed FRFP binding in both superficial and deep tissue sites. As seen in Fig. 3 , a strong signal was observed along the spine and tail, at the knee (arrows), and in deeper regions such as the femoral heads (arrowheads). This activity likely represents mineralization at the growth plates of these bones.
Bone defect healing
Tibias subjected to drilling injury and subsequently intravenously labeled with FRFP showed that the probe binds to both active and inactive bone surfaces. Four days after local injury, the defect site consists of primarily nondifferentiated tissue (Figs. 4A-4D ). Ample alkaline phosphatase activity was seen bordering the original cortex (Fig. 4B, arrowhead) and across the defect site at nonmineralized regions (Fig.  4B, star) . No significant fluorescence signal was observed in these nonmineralized regions, but rather was present at alkaline phosphatase-positive regions of the original cortex (Fig. 4A, arrowhead) . Significant fluorescence was also observed binding to alkaline phosphatase negative bone within the defect region (Figs. 4A and 4B, arrows) . Presumably, this bone represents debris or remnant bone from the drilling process, because it does not seem to be involved in new bone formation.
Eight days after injury, FRFP incorporated readily into mineralized bone surfaces labeled heavily with alkaline When injected on day 8 and examined 6 days later, FRFP signal was observed buried within the bone matrix, with new bone deposited on top (Figs. 4I and 4K, yellow line overlay represents fluorescence signal). Dual labeling with two wavelengths of FRFP separated by 1 day was evident as well (Fig. 4L) , showing independent binding of FRFP to spatially and temporally different regions of regenerating bone.
Orthotopic metastasis
Five mice received intratibial PC-3 tumor injections in one leg to assess FRFP labeling in a bone resorption model. By day 24, one mouse had a visible fracture by X-ray, whereas the remaining four mice showed varying degrees of osteolysis (Figs. 5A, 5C , and 5E). FMT imaging revealed large probe accumulation in the cell-injected limb of both the fractured animal (Fig. 5B ) and the animal with severe osteolysis (Fig. 5D) , suggesting fracture in this animal between days 24 and 28. Fluorescence histology revealed large regions of regenerating bone at the sites of high fluorescent signal with appreciable FRFP binding to surfaces high in alkaline phosphatase activity (Figs. 6A-6D ). In the three animals showing moderate osteolysis by X-ray, none showed fluorescence by FMT at the tumor location (Fig.  5F ). Histology revealed no fracture callus as in the previous mice, but rather a purely osteolytic response, with severe destruction of the cortical bone (Figs. 6E-6H, arrows) . FRFP binds to the scalloped borders of the osteolytic lesion (Fig. 6E, arrows) but seems to bind more abundantly in regions positive for alkaline phosphatase, showing a compensatory osteoblastic response to the regional osteolysis (Figs. 6E and 6F, arrowheads). Osteoclasts were observed sitting in resorption lacunae at the tumor-bone interface (Figs. 6J and 6L, star), consistent with FRFP binding (Fig.  6I, star) .
Fixation and decalcification effects
Fixation of fluorescent-labeled femora with 4% paraformaldehyde had no appreciable effect on FRFP750 signal but induced a 10-40% increase in femoral fluorescence from PS680-and DC680-labeled femora, respectively (Fig.  7) . Tissue autofluorescence in the 750-nm wavelength also increased nearly 40%, but its overall fluorescence was much lower than the other measures (Fig. 7A) . The effect of decalcification on FRFP750 signal was more significant, leading to a 30% decrease in femoral fluorescence after 24 h in 0.5 M EDTA, and >50% decrease in fluorescence on completion of 48 h of decalcification. These results indicate that FRFP750 probe bound to mineral is liberated during decalcification. EDTA treatment induced a modest reduc- 
DISCUSSION
In this study, the far-red pamidronate imaging probe, Osteosense, was shown to bind to three bone regions: active osteoblastic surfaces, indicated by co-localization with robust alkaline phosphatase staining; osteoclastic surfaces, characterized by a scalloped bone border with large osteoclast-like cells present in resorption lacunae; and along quiescent surfaces not labeled by alkaline phosphatase. In vitro binding to inactive dentine surfaces showed that FRFP binding depends on the quantity of mineral present, and decalcification experiments showed that FRFP is removed along with mineral during demineralization procedures, necessitating nondecalcified frozen sectioning throughout the study.
Bisphosphonates have been shown to localize to both osteoblastic and osteoclastic surfaces depending on their side chain and dose. Alendronate deposits underneath both osteoclasts and osteoblasts, but preferentially localizes at the osteoclast-bone interface after low and pharmacologically effective doses. (6, 7) Etidronate also shows a greater affinity for the osteoclast-bone interface at low doses, but labels both osteoclast and osteoblast surfaces equally at pharmacologically effective doses. (7) These findings expand these observations to fluorochrome-labeled pamidronate, which labels both osteoblastic and osteoclastic surfaces when administered in a dose <1% of a therapeutic injection of pamidronate. (12, 13) Binding likely reflects access of a bone surface to the vasculature. In neonatal mice labeled with FRFP, vertebrae showed binding on the periosteal bone collar and within the central mineralizing region of the bone, consistent with development of the primary ossifica- One mouse (A) showed total fracture, whereas a second (C) showed severe osteolysis progressing to fracture by day 28. The three remaining mice (E) showed moderate osteolysis, not progressing to fracture. In vivo FMT imaging reveals FRFP binding in mice progressing to fracture (B and D) but not in three mice with only moderate osteolysis (F). Dotted lines represent tibial and foot outline guided by planar fluorescent and white-light images taken before FMT scan. tion center, (14) whereas mineralized regions further from the primary ossification center were absent of FRFP labeling. We noted a failure of FRFP to bind to some alkaline phosphatase-positive bone surfaces. It is possible that impaired profusion to these surfaces may be responsible for this finding, because of changes in the local vascular environment, which may prevent probe from accessing all available surfaces directly.
Through the use of FMT, we can visualize deep mineralizing structures, including the growth plates in the femoral heads. FMT imaging has been used to monitor deep protease activity associated with tumor metabolism (15) and may be beneficial for monitoring skeletal changes deep within the body or calcifications deep to the surface such as those observed in breast cancer microcalcification or vascular calcification by similar FRFP probes. (16, 17) Most importantly, FMT imaging is quantitative for deep tissue imaging, whereas single channel planar imaging techniques are not, because of tissue attenuation of signal in situ. (9) Despite this sensitivity, FMT imaging could not differentiate FRFP binding to osteoclastic surfaces resulting from osteolytic metastases. These findings are consistent with the inability of 99 mTc-MDP scans to discern purely osteolytic events such as those found in multiple myeloma. (18) Presumably, this results from a relatively low volume of bone labeled at the osteoclast surface compared with the total volume of newly regenerating bone present in the repair models.
FRFP binding in vitro was dependent on mineralization status of the dentine substrate. Bisphosphonates bind to the mineral component of bone in a process that is favored when a hydroxyl group is present as the R 1 side chain. (19) (20) (21) (22) Presumably, the hydroxyl group present on the geminal carbon in pamidronate allows for greater binding of FRFP compared with the bone scan agent 99 mTc-MDP, which is lacking the hydroxyl side chain.
In vitro fluorescence was monotonically increasing up to 0.67 M. At higher concentrations, signal decreased because of fluorochrome-fluorochrome energy transfer, despite increased binding of FRFP observed visually by continued deepening of substrate color (data not shown). For in vivo imaging, FRFP dose should be at an appropriate level to avoid local fluorophore quenching. Based on a 6% bioavailability of alendronate for a comparable injected dose, (7) at the injected imaging dose used in this study, FRFP should bind to bone at concentrations markedly lower than this quenching threshold. Additionally, the attached fluorophore may reduce FRFP binding efficiency compared with unlabeled pamidronate. When externally radiolabeled, pamidronate binds to bone in roughly one half the quantity of pamidronate labeled internally with 14 C. (23) Thus, it is likely that FRFP binding efficiency is lower than unlabeled pamidronate, although the exact amount by which this is reduced is unclear.
Bisphosphonates are used therapeutically to inhibit osteoclast formation and activity, and it is possible that the FRFP, by virtue of its pamidronate backbone, retains some inhibitory functionality. However, the current one-time imaging dose is <1% of a repeatedly administered treatment dose. (12, 13) Furthermore, because the potency of the aminobisphosphonates depends not only on the presence of the nitrogen atom, but on the distance and configuration of that side chain in relation to the central P-C-P structure, (24) binding of the fluorochrome to the nitrogen side group may alter the ability of the nitrogen atom to interact with certain molecular targets. Thus, FRFP binding is not expected to have long-term inhibitory effects on osteoclasts in vivo.
FRFP was buried within bone when examined 6 days after labeling. This finding is similar to previous reports of bone formation proceeding normally on top of radiolabeled bisphosphonates in vivo. (6, 7) Additionally, diffusion of FRFP through the bone matrix to distal regions away from its original binding location is not likely to occur, because diffusion of smaller, nonlabeled bisphosphonates does not seem to occur over time. (6, 7) Thus, FRFP labeling of bone should be an accurate reflection of available bone surface at the time of imaging, and because of the long half-life of pamidronate in bone, (25) could be considered for dual-label imaging of bone deposition over an extended time frame.
Replacing the radiolabeled tag associated with current bone scan agents with a fluorophore offers several benefits. In addition to reducing radiation exposure, fluorescent imaging allows for serial visualization of skeletal events over an extended time period and permits simultaneous multichannel imaging with other fluorescent markers. In addition to the fluorescent bisphosphonates, which may be used to evaluate temporal progression, numerous other probes have been designed to monitor cellular events such as protease activity, (26, 27) cellular apoptosis, (28) (29) (30) integrin expression, (31, 32) matrix dynamics, (33) and altered pH, (34) among others. Combining fluorescent probes with animal models of osteoblast-specific fluorescence (35) (36) (37) (38) (39) will be useful in the study of bone diseases where a complex interplay between cells and their environment results in pathologic bone metabolism.
In addition to being a marker for local bone formation or resorption, fluorescent-labeled bisphosphonates may also be used to monitor local bisphosphonate deposition in disease models such as osteogenesis imperfecta (40) or bone metastasis, (12) where interplay between cells and bisphosphonate play a critical role in rescue of the disease. Similarly, fluorescent bisphosphonates may help elucidate the interplay between drug and bone metabolism in cases of osteopetrosis or osteonecrosis of the jaw associated with high doses of bisphosphonate treatment. (41, 42) In summary, fluorescent-labeled pamidronate is capable of binding bone at regions of formation, resorption, and along some quiescent surfaces. Overall quantity of label seems critical in visualization of probe binding in vivo, and binding likely reflects local access through the vasculature to the mineralized surface. Fluorescent-labeled bisphosphonates provide a convenient means for noninvasive assessment of local bone metabolism in vivo.
FIG. 7.
Effects of fixation and decalcification were tested on mice labeled with FRFP, PS680, and DC750. Fixation has no appreciable effect on FRFP signal; however, decalcification liberates both mineral and FRFP probe bound to mineral in significant quantities.
